http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Arrowhead Pharmaceuticals Inc. (ARWR) Appoints Daniel Apel as CFO
-
Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer
-
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
-
Arrowhead Pharmaceuticals (ARWR) Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy
-
Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy
-
Arrowhead Pharmaceuticals Inc. (ARWR) Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases
-
Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases
-
Arrowhead Pharmaceuticals Inc. (ARWR) expands resources for those affected by FCS
-
Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)
-
Arrowhead Pharmaceuticals (ARWR) Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity
-
Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity
-
Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results
-
Arrowhead Pharmaceuticals (ARWR) Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics (SRPT)
-
Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics
-
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results
-
Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
-
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity
-
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
-
Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases
-
Arrowhead Pharmaceuticals Inc. (ARWR) Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7
-
Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity
-
Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences
-
Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results
-
Arrowhead Pharmaceuticals Announces Global License and Collaboration Agreement with Sarepta Therapeutics for Multiple Clinical and Preclinical Programs
-
Arrowhead Pharmaceuticals Inc. (ARWR) Submits New Drug Application to U.S. FDA for Plozasiran
-
Arrowhead Pharmaceuticals (ARWR) Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran
-
Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
-
Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran
-
Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results
-
Arrowhead Pharmaceuticals to Participate in Upcoming November 2024 Conferences
-
Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We’ll Get There Soon,’ to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome
-
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
-
Arrowhead Pharmaceuticals (ARWR) Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity
-
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity
-
Arrowhead Pharmaceuticals (ARWR) Receives FDA Breakthrough Therapy Designation for Plozasiran
-
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran
-
Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
-
Arrowhead Pharmaceuticals Inc. (ARWR) to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
-
Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
-
Arrowhead Pharmaceuticals Inc. (ARWR) to Advance ARO-INHBE and ARO-ALK7 Into Clinical Studies
-
Arrowhead Pharmaceuticals to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, Into Clinical Studies
-
Arrowhead Pharmaceuticals (ARWR) Announces $500 Million Strategic Financing Facility with Sixth Street
-
Arrowhead Pharmaceuticals Reports Fiscal 2024 Third Quarter Results
-
Arrowhead Pharmaceuticals Announces $500 Million Strategic Financing Facility with Sixth Street
-
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
-
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Third Quarter Results
-
Arrowhead Pharmaceuticals (ARWR) to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial
-
Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial
-
Arrowhead Pharmaceuticals Inc. (ARWR) Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE
-
Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE
